Nature Medicine (NAT MED)

Publisher Nature Publishing Group

Description

The journal publishes original research in all disciplines of biomedical science, according to editorial assessment of a paper's potential interest, impact, and implications for clinical medicine and the biomedical community. The journal favours submissions that represent a conceptual advance or an original approach to understanding the molecular basis of pathogenesis and therapy.

  • Impact factor
    22.46
    Show impact factor history 
     
    Impact factor
    Year
  • Website
    Nature Medicine website
  • Other titles
    Nature medicine
  • ISSN
    1078-8956
  • OCLC
    31218891
  • Material type
    Periodical, Internet resource
  • Document type
    Journal / Magazine / Newspaper, Internet Resource

Publisher details

Nature Publishing Group

  • Pre-print
    • Author can archive a pre-print version
  • Post-print
    • Author cannot archive a post-print version
  • Restrictions
    • 6 months embargo
  • Conditions
    • Published source must be acknowledged and DOI cited
    • Must link to publisher version
    • Publisher's version/PDF cannot be used
    • On funding body's archive, author website and institutional repository
    • If funding agency rules apply, authors may post authors version to their relevant funding body's archive, 6 months after publication
    • Several Journals have paid open access options and licenses (see journal homepages)
    • Creative Commons Licenses available for selected titles.
  • Classification
    ​ yellow

Publications in this journal

Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Follow

Keywords

ap2
 
cancer
 
cell
 
expression
 
here
 
ho-1
 
human
 
infection
 
mice
 
pi
 
resistant
 
respons
 
tumor
 
vascular
 

Related Journals